List view / Grid view
Research & Development (R&D)
Filter the results
Researchers have developed silica spheres to contain cancer therapeutics that melt at certain temperatures and have the potential to improve drug delivery.
The DHSC has confirmed that several pharmaceutical industry bodies have agreed to NDAs regarding plans for a no-deal Brexit.
Pretomanid in combination with bedaquiline and linezolid has been approved by the FDA for treatment-resistant tuberculosis of the lungs.
This series investigates the growing interest from the pharmaceutical industry in cannabinoids. In this first piece, we hear from industry experts about the current situation of the ingredient on the pharmaceutical market.
The European Commission has approved the drug for two indications: chronic lymphocytic leukaemia and Waldenström's macroglobulinemia.
An Ebola clinical trial has been stopped early as Regeneron's REGN-EB3 therapy shows superiority to ZMapp in preventing Ebola deaths.
A treatment for Centronuclear Myopathies has received Orphan Drug Designation from the FDA and will begin Phase I/II trials.
A new systematic review has shown that the speed and quality of clinical trial reports are improved by professional medical writers.
Researchers use the Earth’s biodiversity for pharmaceuticals, but this is under threat due to climate change and habitat destruction. The Nagoya Protocol aims to conserve these resources in a sustainable way.
The NICE and NHS have announced their draft recommendations for the prescribed use of cannabis-based treatments.
2019 has seen a marked increase of antibody biosimilar product approvals in the first half of the year, according to a report.
The global alopecia treatment market is projected to exhibit a CAGR of 4.9 percent from 2018–2026.
A new process developed by the University of Bath protects a TB antigen and a novel vaccine adjuvant from heat damage.
Pharma contract placement was found to increase by 250 percent compared to last year, according to figures from a recruitment firm.